- Joined
- Oct 28, 2008
- Messages
- 2,569
- Reaction score
- 40
A case came up recently, and I was wondering if the toxicology types here might have any input to an interesting dilemma.
Basically, should Digibind be redosed in acutely dig-toxic patients with severe hemodynamic instability on CVVH, and if so, when? Based on the literature I've read, the fab-digoxin complex has a half life of anywhere from 12 to 130 hours in renal failure, with the potential for recurrent toxicity following the dissolution of the immune complex. Patient's in ARF clearly cannot clear either the drug or the complex, so it seems like it's only a matter of time before you'd have to re-dose the Digibind. MARS might be an option based on one case report, but not too many institutions have that capacity yet.
Any clinical experience or literature you might have would be extremely helpful.
Basically, should Digibind be redosed in acutely dig-toxic patients with severe hemodynamic instability on CVVH, and if so, when? Based on the literature I've read, the fab-digoxin complex has a half life of anywhere from 12 to 130 hours in renal failure, with the potential for recurrent toxicity following the dissolution of the immune complex. Patient's in ARF clearly cannot clear either the drug or the complex, so it seems like it's only a matter of time before you'd have to re-dose the Digibind. MARS might be an option based on one case report, but not too many institutions have that capacity yet.
Any clinical experience or literature you might have would be extremely helpful.